StemCell Therapy

Analysts who follow PDS Biotechnology Corp (PDSB) on average expect it to increase 209.68% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.

That average rating earns PDSB an Analyst Ranking of 79, which means it ranks higher than 79 of stocks, based on data compiled by InvestorsObserver.

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.

InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

PDS Biotechnology Corp (PDSB) stock is trading at $2.17 as of 1:08 PM on Wednesday, Dec 9, a loss of -$0.26, or -10.7% from the previous closing price of $2.43. The stock has traded between $2.15 and $2.40 so far today. Volume today is 585,089 compared to average volume of 614,574.

Click Here to get the full report on PDS Biotechnology Corp (PDSB) Stock.

Continued here:
Analyst Rating: Will PDS Biotechnology Corp (PDSB) Stock Outperform the Market? - InvestorsObserver

This entry was posted on December 10, 2020 at 4:55 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |